P21

P21 is a small, blood-brain-barrier-permeable peptide mimetic engineered to reproduce key signaling functions of ciliary neurotrophic factor (CNTF), a neurotrophic cytokine involved in neuronal survival, neurogenesis, and synaptic plasticity. Unlike full-length CNTF or broad neurotrophic blends, P21 is designed to selectively engage the CNTFR-alpha/gp130/LIFR heterotrimeric receptor complex and trigger downstream JAK/STAT3 signaling in a compact, more pharmacologically tractable format for laboratory research use.

Preclinical research on this pharmacophore class has focused on neurodegeneration and synaptic-dysfunction models, particularly in the context of Alzheimer's disease research, where neurotrophic factor small-molecule mimetics have been studied for their capacity to promote neuroregeneration and synaptic repair. Early postnatal neurotrophic treatment paradigms using related mimetics have also been studied for effects on Alzheimer's-like behavioral and synaptic phenotypes in animal models.

Potential Research Applications: - CNTFR-alpha/gp130/LIFR receptor complex signaling and JAK/STAT3 pathway studies - Hippocampal neurogenesis and synaptic plasticity research models - Alzheimer's disease and age-related cognitive decline research models - Comparative neurotrophic factor mimetic pharmacology (vs. CNTF, BDNF, NGF mimetics) - Developmental neuroscience and cognitive pathway research

Market Context: P21 is currently listed by 6 suppliers on this platform, with pricing ranging from approximately $3.14/mg (Top Peptides) to $116/mg (Core Peptides) depending on quantity and supplier — a wide spread typical of a specialty research compound without a single dominant bulk source. Researchers should also review the platform's P-21 (Adamantane) listing, a chemically modified variant of this same pharmacophore.

Cited Research: Kazim SF, Iqbal K (2016). Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Mol Neurodegener. PMID 27400746. Wei W, Liu Y (2021). Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction. J Alzheimers Dis. PMID 34057082.

For laboratory research only. Not for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease. THIS PRODUCT IS NOT FOR HUMAN CONSUMPTION.